



ASIApharm Group Ltd

Press Release – XiMingTing® Release

KEY MEDICAL INSTITUTIONS ENDORSE ASIAPHARM'S PROPRIETARY DRUG – XIMINGTING® – FOR ITS EFFECTIVENESS IN TREATING MENOPAUSAL SYMPTOMS FOLLOWING EXTENSIVE CLINICAL TRIALS

- **10-month extended clinical trials by nine key medical institutions in PRC confirms 80% efficacy rate and safety of XiMingTing® usage in treating menopausal symptoms**
- **Results were presented to over 300 top gynecological researchers and doctors at the second PRC Menopausal Research Forum**
- **XiMingTing® targets a market of over 15.3 million female patients aged 45 to 55 in PRC and possess significant potential for future development**
- **AsiaPharm to expand XiMingTing® penetration in the prescription Gynecological market and bolster its sales and marketing forces for future entry into the OTC market**

Singapore – 19 Jan 2007 – AsiaPharm Group Ltd. (“AsiaPharm” or the “Group” or 亚洲药业集团有限公司), a leading specialty pharmaceutical group in the People’s Republic of China (“PRC”) focusing on the research and development (“R&D”), production and sale of proprietary drugs, natural drugs and drug delivery systems (“DDS”), announced today the conclusion of a 10-month extended clinical trial by nine key medical institutions in the PRC confirming the efficacy and safety of its proprietary drug XiMingTing® (希明婷). The findings – presented to over 300 top gynecological researchers and doctors at the second PRC Menopausal Research Forum – affirms the effectiveness of XiMingTing® in treating menopausal symptoms such as hot flashes, insomnia, night sweats, irritability and mood swings with an efficacy rate of over 80%.

Commissioned by AsiaPharm in line with its commitment to continually improve the lives of patients, the extended clinical trials had aimed to provide both doctors and patients with more evidence pertaining to the efficacy and safety of using XiMingTing® in treating menopausal symptoms. Led by one of PRC’s top medical institutions – Beijing Union Medical College Hospital – the clinical trials encompassed 430 clinical cases which were conducted in nine top-notch hospitals including

Shanghai Fudan Gynecological Hospital, Beijing Gynecological Hospital and Beijing University Gynecology Hospital, validating earlier research findings on the benefits of XiMingTing® usage.

XiMingTing®, a natural drug extracted from the roots of *Cimicifuga foetida*L. (毛茛科植物升麻根茎), is a proprietary drug with a 20-year patent protection from the PRC State Food and Drug Administration (“SFDA”). Launched by AsiaPharm in the first half of 2006, it is currently distributed in 27 hospitals across six key cities such as Beijing, Shanghai, ChongQing and Xi’an.

As a natural drug substitute to Hormone Replacement therapy (“HRT”) which has traditionally been the treatment for menopausal symptoms since the 1940s, XiMingTing® capitalises on the growing demand for substitutes to HRT following reports in 2002 by the United States Women Health Initiative which showed a 26% increase in breast-cancer incidence for women on HRT.

Professor Lin Shou Qing, a renowned gynecologist from the Beijing Medical College Hospital and lead researcher for this study stated during the Menopausal Research Forum, said: “XiMingTing provides gynecologists with a safe and effective alternative in the treatment of menopausal symptoms. This extended clinical trial will provide doctors and patients with a greater understanding and confidence in this natural drug. “

There are approximately 61 million women aged between 45 and 55 in the PRC, according to the fifth population census — which is the common age when menopause begins. Of this figure, over 25% or 15.3 million female patients will require medical treatment for menopause-related ailments. XiMingTing® targets this vast market demand which is currently served by HRT and health supplements.

“XiMingTing® possesses significant potential to be an important revenue generator for AsiaPharm. With its higher efficacy and minimal side-effects, we are confident that XiMingTing will capture a sizable portion of market for menopausal treatment products,” said Mr Liu Dianbo, AsiaPharm’s Executive Chairman.

“The endorsement by China’s key medical institutions and industrial recognition of XiMingTing® stands testament to the efficacy of this new natural. With plans to enlarge the XiMingTing sales team, AsiaPharm is confident of expanding its market penetration by leveraging on the Group’s existing distribution network of over 2000 hospitals in the PRC,” said Mr Liu.

"We are confident that the Group's financial performance will improve significantly from 2007 on the back of our dual-pronged growth strategy to expand market penetration of our existing products and successfully integrating our newly acquired business into the Group's operations," added Mr Liu.

End

Issued on behalf of AsiaPharm Group Ltd. by WeR1 Consultants Pte Ltd

Media Contact Info

WeR1 Consultants Pte Ltd

29 Scotts Road

Singapore 228224

Tel : (65) 6737 4844

Fax : (65) 6737 4944

Yim Jeng Yuh, yimjy@wer1.net, Yeo Wee Kiat, yeowk@wer1.net

About AsiaPharm Group Ltd.

Established in 1994, we are today a leading specialty pharmaceutical group in the People's Republic of China ("PRC") focusing on the research and development, production and sale of natural drugs and drug delivery systems. Our ultra modern facility in Yantai is fully equipped with leading edge technology, fully integrated and GMP certified, enabling us to carry out all aspects of pre-clinical evaluation; from pharmaceutical to pharmacology research, drug safety evaluation and clinical trials; to the full production of our natural drugs. Our successive acquisitions in 2006 and 2007 served to further strengthen our oncology business segment and elevate our position within the PRC Pharmaceutical industry. We currently employ more than 140 researchers and have close collaborative relationships with renowned universities and research institutions to drive our R&D efforts, enabling us to stay at the forefront of specialty pharmaceutical developments. To reach our customers, we have established an extensive distribution network of 35 sales support offices, covering 30 provinces, municipalities, and autonomous regions, reaching out to more than 2,000 hospitals. This is further supported by a strong network of 350 distributors and 500 sales and marketing personnel.